Malcolm McColl
Directeur Général chez Viralytics Ltd.
Profil
Malcolm L.
McColl is the founder and currently serves as the Chairman & Chief Executive Officer of ImmVirX Pty Ltd., a company founded in 2019.
He is also the Chief Executive Officer of Viralytics Ltd., a position he has held since 2013.
In his former roles, Dr. McColl served as the CEO, Director & Managing Director of Viralytics Pty Ltd.
He was also the Vice President-Global Business Development at Mayne Pharma, Inc. from 2007 to 2010.
Additionally, he held the position of Vice President-Business Development at Starpharma Holdings Ltd.Dr. McColl's education includes an MBA from Melbourne Business School and an undergraduate degree from the University of Melbourne.
Postes actifs de Malcolm McColl
| Sociétés | Poste | Début |
|---|---|---|
| Viralytics Ltd. | Directeur Général | 01/01/2013 |
ImmVirX Pty Ltd.
 ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Directeur Général | 01/01/2019 |
Anciens postes connus de Malcolm McColl
| Sociétés | Poste | Fin |
|---|---|---|
Mayne Pharma, Inc.
 Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Corporate Officer/Principal | 01/01/2010 |
| VIRALYTICS LTD. | Directeur Général | - |
| STARPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | - |
Formation de Malcolm McColl
| Melbourne Business School | Masters Business Admin |
| University of Melbourne | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| STARPHARMA HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
Mayne Pharma, Inc.
Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Health Technology |
| Viralytics Ltd. | |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |
